Delafloxacin- Melinta Therapeutics

Drug Profile

Delafloxacin- Melinta Therapeutics

Alternative Names: ABT-492; Baxdela; RX-3341; RX-3341-83; WQ-3034

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wakunaga Pharmaceutical
  • Developer Abbott Laboratories; Melinta Therapeutics
  • Class Antibacterials; Azetidines; Fluoroquinolones; Pyridines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase III Community-acquired pneumonia
  • Phase I Urinary tract infections
  • Discontinued Acute exacerbations of chronic bronchitis; Anthrax; Gonorrhoea; Intra-abdominal infections

Most Recent Events

  • 08 Nov 2017 Delafloxacin is still in phase I trial for Urinary tract infections in USA (Melinta Therapeutics pipeline, November 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Urinary-tract-infections in USA
  • 24 Oct 2017 Additional safety data from the phase III Study 302 trial released by Melinta Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top